{"database": "lobbying", "table": "lobbying_activities", "rows": [[2823601, "5cc8a662-6e58-4719-b9a5-6aa1639bf175", "Q2", "BURRELL INTERNATIONAL GROUP LLC", 401103483, "AVALO THERAPEUTICS", 2022, "second_quarter", "MED", "Medical Countermeasures Development of Therapeutics for COVID-19 and Rare Disease", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2022-07-18T11:37:24-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2823601"], "units": {}, "query_ms": 0.41936198249459267, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}